Brainstem Injury in Pediatric Patients With Posterior Fossa Tumors Treated With Proton Beam Therapy and Associated Dosimetric Factors.

PURPOSE Proton radiation therapy is commonly used in young children with brain tumors for its potential to reduce late effects. However, some proton series report higher rates of brainstem injury (0%-16%) than most photon series (2.2%-8.6%). We report the incidence of brainstem injury and a risk factor analysis in pediatric patients with posterior fossa primary tumors treated with proton radiation therapy at our institution. METHODS AND MATERIALS The study included 216 consecutive patients treated between 2000 and 2015. Dosimetry was available for all but 4 patients. Grade 2 to 5 late brainstem toxicity was assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. RESULTS The histologies include medulloblastoma (n=154, 71.3%), ependymoma (n=56, 25.9%), and atypical teratoid rhabdoid tumor (n=6, 2.8%). The median age at irradiation was 6.6 years (range, 0.5-23.1 years); median dose, 54 gray relative biological effectiveness (Gy RBE) (range, 46.8-59.4 Gy RBE); and median follow-up period, 4.2 years (range, 0.1-15.3 years) among 198 survivors. Of the patients, 83.3% received chemotherapy; 70.4% achieved gross total resection. The crude rate of injury was 2.3% in all patients, 1.9% in those with medulloblastoma, 3.6% in those with ependymoma, and 0% in those with atypical teratoid rhabdoid tumor. The 5-year cumulative incidence of injury was 2.0% (95% confidence interval, 0.7%-4.8%). The median brainstem dose (minimum dose received by 50% of brainstem) in the whole cohort was 53.6 Gy RBE (range, 16.5-56.8 Gy RBE); maximum point dose within the brainstem (Dmax), 55.2 Gy RBE (range, 48.4-60.5 Gy RBE); and mean dose, 50.4 Gy RBE (range, 21.1-56.7 Gy RBE). In the 5 patients with injury, the median minimum dose received by 50% of the brainstem was 54.6 Gy RBE (range, 50.2-55.1 Gy RBE); Dmax, 56.2 Gy RBE (range, 55.0-57.1 Gy RBE); mean dose, 51.3 Gy RBE (range, 45.4-54.4 Gy RBE); and median volume of the brainstem receiving ≥55 Gy RBE (V55), 27.4% (range, 0%-59.4%). Of the 5 patients with injury, 4 had a brainstem Dmax in the highest quartile (≥55.8 Gy RBE, P = .016) and a V55 in the highest tertile (>6.0%) of the cohort distribution (P = .047). Of the 5 patients with injury, 3 were aged >6 years (age range, 4.1-22.8 years), and 4 of 5 patients received chemotherapy and achieved gross total resection. CONCLUSIONS The incidence of injury in pediatric patients with posterior fossa tumors is consistent with previous reports in the photon setting. Our data suggest that when Dmax and V55 are kept <55.8 Gy RBE and ≤6.0%, respectively, the 5-year rate of radiation brainstem injury would be <2%.

[1]  Jeffrey S. Weinberg,et al.  Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.

[2]  L. Ries,et al.  Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. , 1999, Journal of the National Cancer Institute.

[3]  B. Yeap,et al.  Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury. , 2016, International journal of radiation oncology, biology, physics.

[4]  A. King,et al.  Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database , 2017, Cancer.

[5]  M. Gilbert,et al.  Cerebral Radiation Necrosis , 2003, The neurologist.

[6]  T. Merchant,et al.  Necrosis after craniospinal irradiation: results from a prospective series of children with central nervous system embryonal tumors. , 2012, International journal of radiation oncology, biology, physics.

[7]  H. Paganetti,et al.  Proton Treatment Techniques for Posterior Fossa Tumors: Consequences for Linear Energy Transfer and Dose-Volume Parameters for the Brainstem and Organs at Risk. , 2017, International journal of radiation oncology, biology, physics.

[8]  L. Rorke,et al.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Goitein,et al.  Pencil beam scanning proton therapy for pediatric intracranial ependymoma , 2016, Journal of Neuro-Oncology.

[10]  Samuel T Chao,et al.  Challenges with the diagnosis and treatment of cerebral radiation necrosis. , 2013, International journal of radiation oncology, biology, physics.

[11]  T E Schultheiss,et al.  Radiation response of the central nervous system. , 1995, International journal of radiation oncology, biology, physics.

[12]  L. Constine,et al.  Protons, the brainstem, and toxicity: Ingredients for an emerging dialectic , 2014, Acta oncologica.

[13]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[14]  Sairos Safai,et al.  Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. , 2008, International journal of radiation oncology, biology, physics.

[15]  J. Biegel,et al.  Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Ruben,et al.  Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. , 2006, International journal of radiation oncology, biology, physics.

[17]  S. Flampouri,et al.  Incidence and dosimetric parameters of pediatric brainstem toxicity following proton therapy , 2014, Acta oncologica.

[18]  B. Yeap,et al.  Proton Radiation Therapy for Pediatric Central Nervous System Ependymoma: Clinical Outcomes for 70 patients , 2013 .

[19]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.

[20]  P. Poorvu,et al.  Acute toxicity of proton beam radiation for pediatric central nervous system malignancies , 2013, Pediatric blood & cancer.

[21]  R. Mulhern,et al.  White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Korshunov,et al.  The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era , 2004, Cancer.

[23]  D. Machin,et al.  Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. , 2010, European journal of cancer.

[24]  T. Merchant,et al.  Imaging Changes in Very Young Children with Brain Tumors Treated with Proton Therapy and Chemotherapy , 2013, American Journal of Neuroradiology.

[25]  T. MacDonald,et al.  Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. , 2016, Neuro-oncology.

[26]  S. Khatua,et al.  Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system. , 2014, International journal of radiation oncology, biology, physics.

[27]  Zhengjia Chen,et al.  Correlation of Acute and Late Brainstem Toxicities With Dose-Volume Data for Pediatric Patients With Posterior Fossa Malignancies. , 2017, International journal of radiation oncology, biology, physics.

[28]  M. Massimino,et al.  Brain magnetic resonance imaging after high-dose chemotherapy and radiotherapy for childhood brain tumors. , 2008, International journal of radiation oncology, biology, physics.